8 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 17 Phase 2, 5 Phase 1, 1 Phase 3.
Follow Donor Lymphocyte Infusion: new trials by email Literature Review of Donor Lymphocyte Infusion trials Research Report on Donor Lymphocyte Infusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation ASTX727, Donor Lymphocyte Infusion - Allogeneic Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-07-01 | 2026-05-15 | |
| Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies donor lymphocyte infusion, Cyclophosphamide, Busulfan - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 430 | 2022-05-23 | 2026-10-16 |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine - Severe Combined Immunodeficiency | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 4 | 2021-09-02 | 2026-09-16 |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Daratumumab, Donor Lymphocyte Infusion, Laboratory Biomarker Analysis - Minimal Residual Disease, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 1 / Phase 2 | Terminated | Sumithira Vasu | 4 | 2020-01-10 | 2025-05-21 |
| 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 10 | 2018-09-19 | 2026-07-23 |
| Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant donor lymphocyte infusion - Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | Unknown | Peking University People's Hospital | 40 | 2017-03-01 | 2020-03-10 |
| A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 51 | 2017-01-31 | 2026-01-29 |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT donor lymphocyte infusion - Minimal Residual Disease, Donor Lymphocyte Infusion | Phase 2 / Phase 3 | Completed | Nanfang Hospital, Southern Medical University | 206 | 2016-01-01 | 2020-02-25 |
| Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation azacitidine, donor lymphocyte infusion - Acute Myelogenous Leukemia, Acute Lymphoid Leukemia | Phase 2 | Completed | University of California, San Francisco | 17 | 2015-06-02 | 2020-10-12 |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. Donor lymphocyte infusion, Azacytidine - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Carlos Graux, MD, PhD | 50 | 2013-12-01 | 2019-12-10 |
| Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Allogeneic HCT, Donor NK Cell Infusion - Ewing Sarcoma, Neuroblastoma | Phase 2 | Terminated | Monica Thakar | 15 | 2013-03-20 | 2025-03-19 |
| Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation donor lymphocyte infusion - Hematological Malignancy | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 11 | 2010-02-01 | 2013-01-14 |
| Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia Clofarabine for remission induction, Etoposide for remission induction, Cyclophosphamide for remission induction - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Lund University Hospital | 7 | 2009-12-01 | 2021-02-21 |
| Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion donor lymphocyte infusion - Hematologic Neoplasms, Relapse | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2005-12-01 | 2011-01-24 |
| Post Transplant Donor Lymphocyte Infusion Donor Lymphocyte Infusion, Induction Chemotherapy - Leukemia, Myeloid, Chronic, Lymphomas | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 57 | 2004-01-01 | 2019-07-30 |
Hematologic Neoplasms (6) · Leukemia, Myeloid, Acute (6) · Recurrence (5) · Myelodysplastic Syndromes (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Graft vs Host Disease (3) · Neoplasm, Residual (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Multiple Myeloma (2) · Anemia, Aplastic (1) · Brain Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Central Nervous System Neoplasms (1) · Hodgkin Disease (1)
Assistance Publique - Hôpitaux de Paris (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Carlos Graux, MD, PhD (1) · Lund University Hospital (1) · M.D. Anderson Cancer Center (1) · Masonic Cancer Center, University of Minnesota (1) · Monica Thakar (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute (NCI) (1) · Peking University People's Hospital (1) · St. Jude Children's Research Hospital (1) · Sumithira Vasu (1) · Thomas Jefferson University (1) · University of California, San Francisco (1) · Washington University School of Medicine (1)
United States (11) · China (2) · France (2) · Belgium (1) · Sweden (1)
Usama Gergis, MD (3) · Betul Oran, MD (1) · Carlos Graux, MD, PhD (1) · Christopher C Dvorak, M.D. (1) · Christopher G Kanakry, M.D. (1) · Ewelina Mamcarz, MD (1) · Jacek Toporski, MD, PhD (1) · Jeffrey Miller, MD (1) · Matthew Christopher, M.D., Ph.D. (1) · Monica Thakar, MD (1) · Qifa Liu (1) · Sumithira Vasu, MBBS (1)
PMID 17579184, PMID 20650872, PMID 31401903, PMID 32164760, PMID 33150834, PMID 35467818
P50CA171963 (1)